Efficacy and safety of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia / 国际肿瘤学杂志
Journal of International Oncology
; (12): 494-498, 2022.
Article
ي Zh
| WPRIM
| ID: wpr-954311
المكتبة المسؤولة:
WPRO
ABSTRACT
Blinatumomab, as a novel bispecific antibody targeting CD19 and CD3, can induce T lymphocytes to precisely target CD19 positive B lymphocytes to apoptosis. At present, it is the only bispecific antibody approved for the treatment of hematological malignancies in China. Blinatumomab is effective in the treatment of newly diagnosed, relapsed/refractory, minimal residual disease positive patients with B-cell acute lymphoblastic leukemia (B-ALL) . It can improve the survival of the patients and is well tolerated. The further study of blinatumomab can provide theoretical basis and new ideas for induction therapy, salvage therapy and subsequent hematopoietic stem cell transplantation in patients with B-ALL.
النص الكامل:
1
الفهرس:
WPRIM
اللغة:
Zh
مجلة:
Journal of International Oncology
السنة:
2022
نوع:
Article